Cidara Therapeutics Inc (NASDAQ: CDTX) on Friday, plunged -6.26% from the previous trading day, before settling in for the closing price of $0.86. Within the past 52 weeks, CDTX’s price has moved between $0.59 and $1.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -132.14%. With a float of $81.59 million, this company’s outstanding shares have now reached $90.62 million.
Cidara Therapeutics Inc (CDTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cidara Therapeutics Inc is 9.96%, while institutional ownership is 29.71%. The most recent insider transaction that took place on Mar 11 ’24, was worth 14,085. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 21,029 shares at a rate of $0.67, taking the stock ownership to the 258,681 shares. Before that another transaction happened on Mar 11 ’24, when Company’s Chief Medical Officer sold 20,662 for $0.67, making the entire transaction worth $13,839. This insider now owns 347,095 shares in total.
Cidara Therapeutics Inc (CDTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 5.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -132.14% per share during the next fiscal year.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Cidara Therapeutics Inc (CDTX) is currently performing well based on its current performance indicators. A quick ratio of 1.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.07 in the next quarter
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Compared to the last year’s volume of 0.66 million, its volume of 1.02 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 19.24%. Additionally, its Average True Range was 0.12.
During the past 100 days, Cidara Therapeutics Inc’s (CDTX) raw stochastic average was set at 34.61%, which indicates a significant increase from 18.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 135.94% in the past 14 days, which was higher than the 70.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7656, while its 200-day Moving Average is $0.8473. Nevertheless, the first resistance level for the watch stands at $0.8713 in the near term. At $0.9326, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9741. If the price goes on to break the first support level at $0.7685, it is likely to go to the next support level at $0.7270. Now, if the price goes above the second support level, the third support stands at $0.6657.
Cidara Therapeutics Inc (NASDAQ: CDTX) Key Stats
Market capitalization of the company is 73.40 million based on 90,619K outstanding shares. Right now, sales total 64,290 K and income totals -29,800 K. The company made 12,720 K in profit during its latest quarter, and -8,170 K in sales during its previous quarter.
